GERAD1 acknowledgements

Molecular Neuroscience and Reta Lilla Weston Laborato- ries, Institute of Neurology, London, UK; Simon Mead, MRC Prion Unit, Department of Neurodegenerative Dis- ease, UCL Institute of Neurology, London, UK; Nick Fox, and Martin Rossor, Dementia Research Centre, Department of Neurodegenerative Diseases, University College, Lon- don, Institute of Neurology, London, UK; John Collinge, MRC Prion Unit, Department of Neurodegenerative Dis- ease, UCL Institute of Neurology, London, UK; Wolfgang Maier, Frank Jessen, Reiner Heun, and Heike Kölsch, De- partment of Psychiatry, University of Bonn, Bonn, Ger- many; Britta Schürmann, Department of Psychiatry, and Institute for Molecular Psychiatry, University of Bonn, Bonn, Germany;Hendrik van den Bussche, Institute of Pri- mary Medical Care, University Medical Center Hamburg- Eppendorf, Germany; Isabella Heuser, Department of Psy- chiatry, Charité, Berlin, Germany; Johannes Kornhuber, Department of Psychiatry, University of Erlangen, Nürn- berg, Germany; Jens Wiltfang, LVR-Hospital Essen, De- partment of Psychiatry and Psychotherapy, University Du- isburg-Essen, Germany; Martin Dichgans, Institute for Stroke and Dementia Research, and Department of Neurol- ogy, Klinikum der Universität München, Munich, Germa- ny; Lutz Frölich, Central Institute of Mental Health, Med- ical Faculty Mannheim, University of Heidelberg, Germany; Harald Hampel, Department of Psychiatry, Psy- chosomatic Medicine and Psychotherapy, Goethe Univer- sity, Frankfurt, Germany; Michael Hüll, Centre for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsy- chology, Medical School, University of Freiburg, Germany; Dan Rujescu, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig- Maximilian University, Munich, Germany; Alison Goate, Departments of Psychiatry, Neurology and Genetics, Wash- ington University School of Medicine, St. Louis, MO, USA; John S.K. Kauwe, Department of Biology, Brigham Young University, Provo, UT, USA; Carlos Cruchaga, Petra No- wotny, John C. Morris, and Kevin Mayo, Departments of Psychiatry, Neurology and Genetics, Washington Univer- sity School of Medicine, St. Louis, MO, USA; Gill Living- ston, Nicholas J. Bass, Hugh Gurling, and Andrew McQuil- lin, Department of Mental Health Sciences, University College London, London, UK; Rhian Gwilliam, and Pana- giotis Deloukas, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; Markus M. Nöthen, Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany; Peter

Trust, Medical Research Council (MRC), Alzheimer’s Re- search Trust (ART) and the Welsh Assembly Government. ART supported sample collections at the Kings College, London, the South West Dementia Bank, Universities of Cambridge, Nottingham, Manchester, and Belfast. The Bel- fast group acknowledges support from the Alzheimer’s So- ciety, Ulster Garden Villages, N. Ireland R&D Office, and the Royal College of Physicians/Dunhill Medical Trust. The MRC and Mercer’s Institute for Research on Ageing sup- ported the Trinity College group. The South West Dementia Brain Bank acknowledges support from Bristol Research into Alzheimer’s and Care of the Elderly. The Charles Wolfson Charitable Trust supported the OPTIMA group. Washington University was funded by NIH grants, Barnes Jewish Foundation, and the Charles and Joanne Knight Alzheimer’s Research Initiative. Patient recruitment for the MRC Prion Unit/UCL Department of Neurodegenerative Disease collection was supported by the UCLH/UCL Bio- medical Centre. LASER-AD was funded by Lundbeck SA. The Bonn group was supported by the German Federal Ministry of Education and Research (BMBF), Competence Network Dementia, and Competence Network Degenera- tive Dementia, and by the Alfried Krupp von Bohlen und Halbach-Stiftung. The GERAD1 Consortium also used samples ascertained by the NIMH AD Genetics Initiative.

Disclosure statement

The authors declare that there are no conflicts of interest. Approval was obtained from the ethics committee or institutional review board of each institution responsible for the ascertainment and collection of samples. Written in- formed consent was obtained for all individuals who par- ticipated in this study.

Acknowledgements

We thank all of our collaborators who provided data for this study (ARUK and GERAD1 consortia), together with the Alzheimer’s disease centers that collected the samples, as well as the subjects and their families, whose help and participation made this work possible. This work was sup- ported by Alzheimer’s Research UK and the Big Lottery Fund.

References

Arking, D.E., Atzmon, G., Arking, A., Barzilai, N., Dietz, H.C., Association between a functional variant of the KLOTHO gene high-density lipoprotein cholesterol, blood pressure, stroke, and gevity. Circ. Res.

,

–

Atzmon, G., Schechter, C., Greiner, W., Davidson, D., Rennert, G., zilai, N.,

Clinical phenotype of families with longevity. J. Geriatr. Soc.

,

–

Aulchenko, Y.S., Ripke, S., Isaacs, A., van Duijn, C.M., 2007. GenABEL: an R library for genome-wide association analysis. Bioinformatics 23,

Frolich, L., Hampel, H., Hull, M., Rujescu, D., Goate, A.M., Kauwe, J.S., Cruchaga, C., Nowotny, P., Morris, J.C., Mayo, K., Sleegers, K., Bettens, K., Engelborghs, S., De Deyn, P.P., Van Broeckhoven, C., Livingston, G., Bass, N.J., Gurling, H., M

uillin, A., Gwilliam, R., Deloukas, P., Al-Chalabi, A., Shaw, C.E., Tsolaki, M., Singleton, A.B., Guerreiro, R., Muhleisen, T.W., Nothen, M.M., Moebus, S., Jockel, K.H., Klopp, N., Wichmann, H.E., Carrasquillo, M.M., Pankratz, V.S., Younkin, S.G., Holmans, P.A., O’Donovan, M., Owen, M.J., Williams, J.,

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat. Genet.

,

–

Herskind, A.M., M

ue, M., Holm, N.V., Sørensen, T.I., Harvald, B., Vaupel, J.W.,